NCT02523196View on ClinicalTrials.gov

Correlation and Comparison of the HepQuant® Disease Severity Index (DSI) With Hepatic Venous Pressure Gradient (HVPG)

PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

February 23, 2017

Study Completion Date

February 23, 2017

Conditions
Liver Disease
Interventions
DRUG

HepQuant-SHUNT (Drug and Device) #65,123 (4D-cholate) and IND #65,121 (13C-cholate)

The HQ-SHUNT test is being evaluated for safety and effectiveness as an alternative to Hepatic Venous Pressure Gradient (HVPG) testing in patients with liver disease

DEVICE

Hepatic Venous Pressure Gradient (HVPG)

Hepatic Venous Pressure Gradient (HVPG) is a test for patients with liver disease

Trial Locations (1)

80045

University of Colorado Denver (Leprino Building), Aurora

All Listed Sponsors
lead

University of Colorado, Denver

OTHER

NCT02523196 - Correlation and Comparison of the HepQuant® Disease Severity Index (DSI) With Hepatic Venous Pressure Gradient (HVPG) | Biotech Hunter | Biotech Hunter